Trademarkia Logo

Canada

C$
Trademark Search in Canada
GCBT (& DESIGN)

View On IC.GC.CA

GCBT (& DESIGN)
ABANDONED SECTION 36

on 12 Jan 2022

Last Applicant/ Owned by

GREEN CROSS HOLDINGS CORPORATION A LEGAL ENTITY

107, Ihyeon-ro 30beon-gilGiheung-gu, Yongin-siGyeonggi-do

KR

Serial Number

1912822 filed on 1st Aug 2018

Correspondent Address

ROBIC AGENCE PI S.E.C./ ROBIC IP AGENCY LP

630, boul. René-Lévesque Ouest20e étageMontréal

QUÉBEC

CA

H3B1S6

GCBT (& DESIGN)

Trademark usage description

recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry. pharmaceuticals for the preventi Read More

Vienna Information

24 . 13 . 1

Greek cross, St. Andrew's crossCroix grecque ou de Saint-André

24 . 13 . 14

Crosses accompanied by an inscriptionCroix accompagnée d'une inscription

25 . 5 . 3

Backgrounds divided into two, diagonallyFonds partagés en deux en oblique

29 . 1 . 3

GreenVert

29 . 1 . 2

Yellow, goldJaune, or

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

29 . 1 . 4

BlueBleu

Classification Information

Class [001]
Recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry.

Classification kind code

11

Class [005]
Pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza; blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors; human vaccines, influenza vaccines and vaccine components; therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza.

Classification kind code

11

Class [035]
Wholesale distributorships, namely, pharmaceutical products, namely, pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza; Wholesale distributorships, namely, pharmaceutical products, namely, blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors, human vaccines, influenza vaccines and vaccine components, recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry, therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza; retail store services, namely, pharmaceutical products, namely, pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza; retail store services, namely, pharmaceutical products, namely, blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors, human vaccines, influenza vaccines and vaccine components, recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry, therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza; business agency services, namely, export and import agencies in the field of pharmaceutical products, namely, pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza; business agency services, namely, export and import agencies in the field of pharmaceutical products, namely, blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors, human vaccines, influenza vaccines and vaccine components, recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry, therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza; wholesaling, distributorships, and retailing of pharmaceutical products, namely, pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza for others; wholesaling, distributorships, and retailing of pharmaceutical products, namely, blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors, human vaccines, influenza vaccines and vaccine components, recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry, therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza for others; pharmaceutical products procurement services for others, namely, purchasing pharmaceutical products, namely, pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza for other businesses; pharmaceutical products procurement services for others, namely, purchasing pharmaceutical products, namely, blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors, human vaccines, influenza vaccines and vaccine components, recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry, therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza for other businesses; wholesaling, distributorships, and retailing of cosmetics for others; wholesale store services, namely, toothpaste.

Classification kind code

11

Class [036]
Financial intermediary services, namely, facilitating the channeling of funds between lenders and borrowers by connecting those with a financial surplus with those having a financial deficit in the field of pharmaceutical products; financial intermediary services, namely, facilitating the channeling of funds between lenders and borrowers by connecting those with a financial surplus with those having a financial deficit in the field of medical machines and apparatus.

Classification kind code

11

Class [042]
Research and development in the field of pharmaceuticals, namely, pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza, blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors, human vaccines, influenza vaccines and vaccine components, recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry, therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza, vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies; laboratory and scientific research in the field of pharmaceuticals, namely, pharmaceuticals for the prevention and treatment of Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Hunter Syndrome, Hemophilia A, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome and influenza, blood plasma-derivatives, namely albumins, immunoglobulins, and blood clotting factors, human vaccines, influenza vaccines and vaccine components, recombinant proteins, namely enzymes and blood clotting factors, for use in the medical and pharmaceutical industry, therapeutic antibodies for the prevention and treatment of Hepatitis B, influenza, vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies.

Classification kind code

11

Mark Details

Serial Number

1912822

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 42
on 13th Jan 2021		Advertised
Submitted for opposition 26
on 21st Oct 2020		Approved
Submitted for opposition 27
on 21st Oct 2020		Approval Notice Sent
Submitted for opposition 15
on 3rd Mar 2020		Correspondence Created
Submitted for opposition 15
on 24th Apr 2019		Correspondence Created
Submitted for opposition 22
on 20th Nov 2018		Search Recorded
Submitted for opposition 20
on 20th Nov 2018		Examiner's First Report
Submitted for opposition 31
on 3rd Aug 2018		Formalized
Submitted for opposition 1
on 2th Aug 2018		Created
Submitted for opposition 30
on 1st Aug 2018		Filed